Publication | Open Access
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
6.6K
Citations
29
References
2014
Year
LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
| Year | Citations | |
|---|---|---|
1999 | 9K | |
1991 | 8K | |
1999 | 5.1K | |
1987 | 5.1K | |
1999 | 4.9K | |
2001 | 3.1K | |
2001 | 3.1K | |
2010 | 3K | |
2000 | 2.9K | |
2000 | 1.8K |
Page 1
Page 1